Raymond James initiated coverage on Jazz Pharma
$JAZZ
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James initiated coverage of Jazz Pharma with a rating of Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/7/2025 | $145.00 → $179.00 | Neutral → Buy | UBS |
| 2/26/2025 | Overweight → Neutral | Cantor Fitzgerald | |
| 2/13/2025 | $130.00 → $170.00 | Equal Weight → Overweight | Wells Fargo |
| 12/12/2024 | $140.00 → $175.00 | Equal-Weight → Overweight | Morgan Stanley |
| 6/5/2024 | $169.00 | Buy | Goldman |
| 1/3/2024 | $160.00 | Outperform | Robert W. Baird |
| 11/27/2023 | $170.00 → $135.00 | Buy → Neutral | UBS |
| 9/29/2023 | Mkt Perform | Raymond James |
DEFA14A - Jazz Pharmaceuticals plc (0001232524) (Filer)
DEF 14A - Jazz Pharmaceuticals plc (0001232524) (Filer)
144 - Jazz Pharmaceuticals plc (0001232524) (Subject)